The Board of Directors of Guerbet, convened on January 28, 2026, upon the recommendation of the Nominations and Compensation Committee, decided to appoint Karim Boussebaa as the CEO of the group. The appointment will be effective from February 2, 2026. Karim Boussebaa is a graduate from the National School of Advanced Sciences and Technologies and holds an MBA from Westminster College (Salt Lake City, USA). He has over 25 years of international experience in the health and medical technology sectors, having previously held leadership positions in leading groups in the fields of medical imaging and medical devices.
Previous Interim CEO
Free · Every morning
Technical market signals, before the opening bell.
Bullish and bearish momentum, analyst changes, stocks to watch — automatically computed from Euronext data.
✓ Before 9 AM every morning✓ Euronext data✓ AI-powered analysis
You're in — subscription confirmed!
Your first edition is on its way. Check your spam folder and add us to your contacts.
An error occurred.
Indicative data. No investment advice. Unsubscribe at any time.
Gratuit · chaque matin
Ne ratez plus rien sur vos actions
La tendance derrière les cours. L'essentiel des valeurs Euronext en quelques minutes.
📈les valeurs en mouvement, sur la durée
🎯les objectifs d'analystes qui évoluent
📰les actualités qui font bouger les cours
tendance · 6 séances
✓ C'est fait, vous êtes inscrit !
Votre première édition arrive bientôt. Pensez à vérifier vos spams.
Une erreur est survenue.
CAC 40 · SBF 120 · données indicatives · aucun conseil en investissement · désinscription à tout moment.
Jérôme Estampes, who served as the interim CEO, will resume his role as Director of Group Financial Affairs and SVP of Business Development and Licenses starting February 2, 2026.
Related
SectorDispositifs médicaux et optique›Dispositifs médicaux / imagerie
Free · every morning · before 9am
Never miss a move on your stocks
The trend behind the prices · Euronext
✓ You're in! Check your spam folder.
An error occurred.
Context
Period
Period: 9M 2026
Key reported figures
Revenue: 573,8 millions d'euros
Quarterly revenue: 573,8 millions d'euros
Revenue growth: -2,2 %
Guidance from the release
Strongly negative free cash flow of between -€50 million and -€70 million, due to the expected decrease in restated EBITDA, the increase in the CAPEX plan and non-recurring restructuring costs
Risks mentioned
Ongoing contraction in sales in China due to policy to sharply reduce healthcare spending and gradual elimination of intermediaries
Planned slowdown in subcontracting activities at Gadopiclenol production site with Fill & Finish ending at end-2026
Continued normalisation at Raleigh industrial site with restructuring costs and redundancy plan in France
Opportunities identified
Strong momentum in Interventional Radiology business, up 6.6% with Lipiodol® driving growth in vascular embolization market
Recovery in activity in France and positive contribution from EMEA, Americas and Asia regions excluding China
Dynamic sales of Elucirem™ product offsetting some of the decline in other divisions
Outlook / guidance
Management commentary: For 2026, the Group's targets are: Revenue stable or showing a slight decrease at CER and on a like-for-like basis. Restated EBITDA margin rate of around 8%, including around €35 million related to the costs of the remediation plan at the Raleigh site. Strongly negative free cash flow of between -€50 million and -€70 million, due to the expected decrease in restated EBITDA, the increase in the CAPEX plan and non-recurring restructuring costs linked to the Group's transformation plan, including in particular the redundancy plan in France.
The information presented in this article is provided for informational purposes only and does not constitute an investment recommendation, an incentive to buy or sell a financial asset, or investment advice. Readers are invited to conduct their own research before making any decision.
Investments in the stock market involve risks, including the risk of capital loss. Past performance of an asset or market is no guarantee of future results. Any investment decision should be made taking into account your personal financial situation, objectives and risk tolerance.
